Business Description
Ovid Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US6904691010
Description
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 6.61 | |||||
Equity-to-Asset | 0.61 | |||||
Debt-to-Equity | 0.18 | |||||
Debt-to-EBITDA | -0.28 | |||||
Interest Coverage | N/A | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -0.82 | |||||
Beneish M-Score | -3.28 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -69.7 | |||||
3-Year EBITDA Growth Rate | 16.2 | |||||
3-Year EPS without NRI Growth Rate | 17.9 | |||||
3-Year FCF Growth Rate | 9.9 | |||||
3-Year Book Growth Rate | 23.2 |
Momentum Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 45.32 | |||||
9-Day RSI | 46.69 | |||||
14-Day RSI | 47.41 | |||||
6-1 Month Momentum % | -12.54 | |||||
12-1 Month Momentum % | -9.64 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 9.55 | |||||
Quick Ratio | 9.55 | |||||
Cash Ratio | 9.22 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -2.4 | |||||
Shareholder Yield % | -0.06 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Operating Margin % | -15122.96 | |||||
Net Margin % | -13351.53 | |||||
FCF Margin % | -11713.52 | |||||
ROE % | -47.32 | |||||
ROA % | -37.18 | |||||
ROIC % | -192.11 | |||||
ROC (Joel Greenblatt) % | -385.77 | |||||
ROCE % | -44.92 | |||||
Years of Profitability over Past 10-Year | 1 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PS Ratio | 504.84 | |||||
PB Ratio | 2.5 | |||||
Price-to-Tangible-Book | 2.5 | |||||
EV-to-EBIT | -2.05 | |||||
EV-to-EBITDA | -2.11 | |||||
EV-to-Revenue | 310.18 | |||||
EV-to-Forward-Revenue | 323.42 | |||||
EV-to-FCF | -2.65 | |||||
Price-to-Net-Current-Asset-Value | 4.13 | |||||
Price-to-Net-Cash | 4.43 | |||||
Earnings Yield (Greenblatt) % | -48.78 | |||||
FCF Yield % | -20.95 |